TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* female of non-childbearing potential~* Treated with maximally tolerated dose of metformin (≥ 1500mg/day) for at least 10 weeks prior to enrolment.~* Patients with HbA1c ≥ 7.5 but ≤ 10% at enrolment visit (Visit 1) can enter cohort 1.Patients with HbA1c between \>10 % and \<12 % can enter the open-label arm with AZD1656 (cohort 2)~Exclusion Criteria:~* Significant cardiovascular event within the last 6 months prior to enrolment or heart failure New York Heart Association (NYHA) class III-IV.~* Impaired renal function in terms of GFR\<60 ml/min, based on Modification of Diet in Renal Disease Study Group (MDRD) calculation.~* Use of warfarin or amiodarone within 3 months prior to enrolment (screening) and use of potent CYP450 inhibitors, eg, ketoconazole and/or macrolide antibiotics within 14 days before randomisation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD1656
- 2 (Type: EXPERIMENTAL): AZD1656
- 3 (Type: EXPERIMENTAL): AZD1656
- 4 (Type: EXPERIMENTAL): AZD1656
- 5 (Type: EXPERIMENTAL): AZD1656
- 6 (Type: PLACEBO_COMPARATOR): None
- 7 (Type: ACTIVE_COMPARATOR): Glipizide administered to 1 group of patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with postmenopausal osteoporosis~Exclusion Criteria:~* Bilateral hip replacements~* Esophageal abnormalities~* Metabolic bone disease (example - Vitamin D deficiency)~* Medications that would affect the breakdown or build-up of bone turnover

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alendronate 70 mg (Type: EXPERIMENTAL): Alendronate sodium, 70 mg, orally once weekly for up to 24 months
- Risendronate 35 mg (Type: ACTIVE_COMPARATOR): Risendronate, 35 mg, orally once weekly for up to 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers with a body mass index between 18 and 30 kg/m2 (inclusive) and body weight not less than 50 kg~Exclusion Criteria:~* of or current medical illness deemed clinically significant by the Investigator (study physician)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Treatment for Severe Inflammatory Acne Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female subjects, 12 years of age or older at Screening visit.~2. Subjects with a clinical diagnosis of severe inflammatory acne (IGA score of 4).~3. Subjects with 4 or fewer nodules or cysts \> 1 cm in diameter on the face.~4. Subjects 18 years of age or older must read and sign the Informed Consent Form, which includes Photography Consent and HIPAA authorization, prior to any participation in the study. Consent will be obtained prior to any study-related procedures. Subjects under the age of 18 years must sign an Assent to Participate Form to participate in the study and must have one parent or guardian read and sign the Informed Consent Form prior to any study-related procedure. (The parent or guardian is not required to attend the following visits unless requested.)~Key Exclusion Criteria:~1. Subjects with nodulocystic or conglobate acne, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.).~2. Subjects with 5 or more acne nodules or cysts \> 1 cm in diameter on the face at Screening and Baseline visits.~3. Female subjects who are pregnant, nursing, or planning a pregnancy during the study.~4. Subjects who have used any systemic therapy directed at improving acne, including antibiotics, within 30 days prior to Baseline visit.~5. Subjects who are at risk in terms of precautions, warnings, and contraindications for the investigational study drugs (see Appendix 14.1 for package inserts for adapalene 0.3%/benzoyl peroxide 2.5% gel and doxycycline hyclate Tablets).~6. Subjects with any other condition or circumstance which, in the Investigator's opinion, may put the subject at risk (e.g., a history of significant renal disease with impairment of renal function), confound the study results, or interfere with the subject's participation in the study.~7. Sponsor and study site staff, relatives of staff members, or other individuals who would have access to the clinical study protocol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acne treatment (Type: EXPERIMENTAL): Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Crano-cure inTreatment of Urinary Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 to 60 years with symptomatic acute urinary tract infection.~  * Willing to participate in the study~ * Non-pregnant adult females.~ * Clinical signs and symptoms of a UTI (e.g., dysuria, frequency, urgency to urinate, Burning sensations during urination, Hematuria, suprapubic pain) with onset of symptoms \< 72 hours prior to study entry.~ * One positive pre-treatment clean-catch midstream urine culture within 48 hours of enrollment in the study, defined as \> 105 CFU/mL.~ * Patients having all socioeconomic classes including lower, middle and higher.~ * In-vitro susceptibility testing of the uropathogen to test and control drug.~Exclusion Criteria:~* • Women who are pregnant, nursing, or not using a medically accepted, effective method of birth control. If an antimicrobial agent is to be studied for the treatment of UTI in pregnant women, this proposal should be justified, the risk/benefit expectations explained, and the issue presented to the division.~  * Three or more episodes of acute uncomplicated UTI in the past 12 months.~ * Patients with evidence of factors predisposing to the development of urinary tract infections, including calculi, stricture, primary renal disease (e.g., polycystic renal disease), or neurogenic bladder.~ * Patients with onset of symptoms 96 hours or more prior to entry.~ * Patients with a temperature \> 1010 F, flank pain, chills, or any other manifestations suggestive of upper urinary tract infection.~ * Patients with known or suspected hypersensitivity to the test or control drug.~ * Patients who received treatment with other antimicrobials within 48 hours prior to entry.~ * Patient suffering in chronic illness Diabetes mellitus, chronic liver diseases

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
- control group (Type: ACTIVE_COMPARATOR): No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults and children 5 years of age and older~Exclusion Criteria:~* Children under 5 years of age

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personal Risk + Loss Protection (Type: EXPERIMENTAL): Personal Risk + Loss Protection
- Personal Risk + Lottery Incentive (Type: EXPERIMENTAL): Personal Risk + Lottery Incentive
- Family Risk + Loss Protection (Type: EXPERIMENTAL): Family Risk + Loss Protection
- Family Risk + Lottery Incentive (Type: EXPERIMENTAL): Family Risk + Lottery Incentive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of non-infectious intermediate, posterior or pan-uveitis~Exclusion Criteria:~* any ocular trauma within the past 6 months in the study eye~* any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study treatment, or any prior use of Retisert™ in the study eye~* any uncontrolled systemic disease that would preclude participation in the study or put the subject at risk due to study treatment or procedures~* have a known HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated~* are monocular~* have ocular hypertension~* history of any intraocular surgery in the study eye~* presence of an anterior staphyloma in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triamcinolone acetonide (Triesence®) (Type: EXPERIMENTAL): TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years~* History of gout - crystal proven or historical as defined by ACR criteria listed above~* Serum urate level \> 6.8 mg/dl~Exclusion Criteria:~* Stage 4 or 5 Chronic Kidney Disease (CKD) - defined as eGFR \< 30 ml/min/1.73 m2~* Women less than 50 years of age~* Patients with a history of prior solid organ / hematopoietic transplantation~* Previous allergy or intolerance to allopurinol or febuxostat~* Patients who are not candidates for any of the recommended prophylactic medications (colchicine, naprosyn or glucocorticoids)~* Patients who in the opinion of the investigator have a high genetic risk for allopurinol hypersensitivity syndrome (AHS\*) unless they have been found to be negative for HLA B5801.~* Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose \> 300 mg/day~* Prior febuxostat use~* Patients with malignancies that are currently active with exception of non-melanoma skin cancer~* Patients with serum uric acid levels \>15 mg/dl~* Patients with myelodysplasia and hemoglobin of \< 8.5 mg/dL~* Patients with chronic liver disease with more than one of the following:~  * INR \> 1.7, not on Warfarin therapy~ * Bilirubin 2 mg/dL~ * Serum albumin \< 3.5 mg/dL~ * Ascites~ * Encephalopathy~* Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, probenecid, lesinurad or pegloticase~* Enrollment in another randomized interventional clinical trial~* Any severe medical condition that, in the enrolleer's opinion, is likely to compromise the participant's ability to complete the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopurinol / Sham Comparator (Febuxostat) (Type: ACTIVE_COMPARATOR): Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
- Febuxostat / Sham Comparator (Allopurinol) (Type: ACTIVE_COMPARATOR): Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of couples with an indication for COH and IVF or ICSI;~* \>=18 and \<=39 years of age at the time of signing informed consent;~* BMI \>=18 and \<=29 kg/m\^2;~* Normal menstrual cycle length: 24-35 days;~* Ejaculatory sperm (use of donated and/or frozen sperm is allowed);~* Willing and able to sign informed consent.~Exclusion Criteria:~* History of/or any current (treated) endocrine abnormality;~* History of ovarian hyperstimulation syndrome (OHSS);~* History of/or current polycystic ovary syndrome (PCOS) or current polycystic ovaries according to USS (at least 10 follicles of 2-8 mm in each ovary);~* More than three unsuccessful COH cycles since the last established ongoing pregnancy (if applicable);~* History of non- or low ovarian response to FSH/hMG treatment;~* Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual cycle day 2-7) as measured by the local laboratory (FSH, LH, E2, P, total T, TSH and prolactin):~* Any clinically relevant abnormal laboratory value;~* Less than 2 ovaries;~* Any ovarian and/or abdominal abnormality interfering with ultrasound examination;~* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);~* Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease;~* History of presence of alcohol or drug abuse within 12 months prior to signing informed consent;~* Previous use of Org 36286;~* Use of hormonal preparations within 1 month prior to randomization;~* Hypersensitivity to Org 32489 (Puregon®) and/or Org 37462 (Orgalutran®) and/or Pregnyl® or any of their components;~* Administration of investigational drugs within three months prior to signing informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 60 µg Org 36286 (corifollitropin alfa)
- 2 (Type: EXPERIMENTAL): 120 µg Org 36286 (corifollitropin alfa)
- 3 (Type: EXPERIMENTAL): 180 µg Org 36286 (corifollitropin alfa)
- 4 (Type: ACTIVE_COMPARATOR): Follitropin beta injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatments for Psychogenic Nonepileptic Seizures (NES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Video electroencephalogram (vEEG) confirmed diagnosis of NES~* Have at least one nonepileptic seizure per month~* Comorbid diagnosis of either depression, anxiety, or post traumatic stress disorder (PTSD)~* Able to complete self report symptom scales~* Not receiving optimized antidepressant medication~Exclusion Criteria:~* Equivocal electroencephalogram (EEG) findings~* Current suicidality, litigation, or self-mutilation~* Using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan~* Allergy/sensitivity to sertraline~* Current alcohol/drug dependence~* Serious medical illness requiring current hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- sertraline (Type: ACTIVE_COMPARATOR): flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
- placebo (Type: PLACEBO_COMPARATOR): flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Exacerbation of COPD (at least Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] severity stage II)~* Smoking history of \> 10 pack years~Exclusion Criteria:~* Signs of severe exacerbation (arterial pH \< 7.26 or pCO2 \> 9.3 kPa)~* History of asthma~* Significant or unstable co-morbidity~* Participated in another study 4 weeks before admission~* Previously randomized to this study~* Findings on chest radiography other than those fitting with signs of COPD~* Known hypersensitivity to prednisolone~* Non-compliant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatient children of either gender \[M/F: 1:1\] undergoing venipuncture or peripheral venous cannulation at the antecubital fossa or back of hand. Children must have sufficient cognitive skills to identify faces depicting extremes of pain on the Wong-Baker FACES Pain Rating Scale, (ages 3-12) and/or the extremes of pain on a 100 VAS (ages 8-18).~* Ages 3-7, 8-12, 13-18 years inclusive. Informed consent forms must have been approved by the appropriate IRB. Signed informed consent must have been granted by the parent/legal guardian and assent to participate should have been sought (either verbally or in writting) from each child.~* In females of childbearing potential who in the judgement of the investigator or designee were sexually active, a negative preganancy test must have been documented prior to enrollment. A negative urine preganancy test was required in all teenage girls over the age of 14 years. Surgically sterile females do not require a pregnancy test.~Exclusion Criteria:~* Previous history of allergic reactions to any local anesthetic. Any medical condition or instability that in the judgement of the investigator might have adversely impacted the conduct of the study and the collection of data.~* Subjects in whom the investigator determined that venipuncture could not be accomplished cleanly.~* Active local infection or other skin pathology on the dorsum of the hand. Subjects with tattos, surgical scars, ports, implantable devices or a skin condition that may have interfered with placement of study treatment or skin site assessments.~* Female subjects who were pregnant or lactating; females with a positive serum or urine pregnancy test; females of childbearing potential who were not using adequate contraception.~* Prior participation in an ALGRX 3268 study.~* Venipuncture at the proposed site within the prior 2 weeks (longer if bruising was apparent).

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete